Teclistamab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Teclistamab" in English language version.

refsWebsite

Global rank English rank

15web.archive.org

1^st place

6fda.gov

447^th place

338^th place

6nih.gov

4^th place

3jnj.com

low place

3doi.org

2^nd place

2tga.gov.au

3,984^th place

2,622^nd place

2europa.eu

68^th place

117^th place

1hpfb-dgpsa.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1handle.net

102^nd place

76^th place

canada.ca

"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]". Health Canada. 26 October 2023. Archived from the original on 3 January 2024. Retrieved 3 January 2024.

doi.org

Kang C (November 2022). "Teclistamab: First Approval". Drugs. 82 (16): 1613–1619. doi:10.1007/s40265-022-01793-1. PMC 9646474. PMID 36352205.
Pan D, Richter J (2023). "Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody". Cancer Management and Research. 15: 741–751. doi:10.2147/CMAR.S372237. PMC 10368105. PMID 37497430.
Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M (October 2023). "Teclistamab-cqyv in multiple myeloma". European Journal of Haematology. 112 (3): 320–327. doi:10.1111/ejh.14121. PMID 37848191.

europa.eu

ema.europa.eu

"Tecvayli EPAR". European Medicines Agency. 18 July 2022. Archived from the original on 10 December 2022. Retrieved 14 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Tecvayli Product information". Union Register of medicinal products. 12 December 2022. Archived from the original on 3 March 2023. Retrieved 3 March 2023.

fda.gov

"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma". U.S. Food and Drug Administration (FDA). 25 October 2022. Archived from the original on 27 October 2022. Retrieved 28 October 2022. This article incorporates text from this source, which is in the public domain.
"Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Tecvayli". U.S. Food and Drug Administration (FDA). 23 November 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
"Tecvayli: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 27 October 2022. Retrieved 27 October 2022.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

handle.net

hdl.handle.net

World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Details for: Tecvayli". Health Canada. 20 October 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.

jnj.com

"Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody Tecvayli (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)". Janssen (Press release). 22 July 2022. Archived from the original on 30 July 2022. Retrieved 30 July 2022.
"Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.
"U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". Janssen Pharmaceutical Companies. 25 October 2022. Archived from the original on 10 March 2024. Retrieved 26 October 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kang C (November 2022). "Teclistamab: First Approval". Drugs. 82 (16): 1613–1619. doi:10.1007/s40265-022-01793-1. PMC 9646474. PMID 36352205.
Pan D, Richter J (2023). "Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody". Cancer Management and Research. 15: 741–751. doi:10.2147/CMAR.S372237. PMC 10368105. PMID 37497430.
Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M (October 2023). "Teclistamab-cqyv in multiple myeloma". European Journal of Haematology. 112 (3): 320–327. doi:10.1111/ejh.14121. PMID 37848191.

ncbi.nlm.nih.gov

Kang C (November 2022). "Teclistamab: First Approval". Drugs. 82 (16): 1613–1619. doi:10.1007/s40265-022-01793-1. PMC 9646474. PMID 36352205.
Pan D, Richter J (2023). "Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody". Cancer Management and Research. 15: 741–751. doi:10.2147/CMAR.S372237. PMC 10368105. PMID 37497430.

dailymed.nlm.nih.gov

"Tecvayli- teclistamab injection". DailyMed. 31 October 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.

tga.gov.au

"Tecvayli". Therapeutic Goods Administration (TGA). 28 June 2023. Archived from the original on 19 November 2023. Retrieved 10 September 2023.
"Tecvayli (Janssen-Cilag Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 19 November 2023. Retrieved 10 September 2023.

web.archive.org

"Tecvayli". Therapeutic Goods Administration (TGA). 28 June 2023. Archived from the original on 19 November 2023. Retrieved 10 September 2023.
"Tecvayli (Janssen-Cilag Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 19 November 2023. Retrieved 10 September 2023.
"Details for: Tecvayli". Health Canada. 20 October 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]". Health Canada. 26 October 2023. Archived from the original on 3 January 2024. Retrieved 3 January 2024.
"Tecvayli- teclistamab injection". DailyMed. 31 October 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
"Drug Approval Package: Tecvayli". U.S. Food and Drug Administration (FDA). 23 November 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
"Tecvayli EPAR". European Medicines Agency. 18 July 2022. Archived from the original on 10 December 2022. Retrieved 14 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody Tecvayli (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)". Janssen (Press release). 22 July 2022. Archived from the original on 30 July 2022. Retrieved 30 July 2022.
"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma". U.S. Food and Drug Administration (FDA). 25 October 2022. Archived from the original on 27 October 2022. Retrieved 28 October 2022. This article incorporates text from this source, which is in the public domain.
"Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.
"Tecvayli: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 27 October 2022. Retrieved 27 October 2022.
"U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". Janssen Pharmaceutical Companies. 25 October 2022. Archived from the original on 10 March 2024. Retrieved 26 October 2022.
"Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.
"Tecvayli Product information". Union Register of medicinal products. 12 December 2022. Archived from the original on 3 March 2023. Retrieved 3 March 2023.